Proven vaccine technologies, applicable for large scale manufacturing, for rapid response against novel coronavirus, 2019-nCoV

The objective of this Call for Proposals is to rapidly develop and manufacture a proven vaccine approach that can be used against the 2019-nCoV. This call aims to complement CEPI’s 2019-nCoV portfolio and candidates should have large-scale manufacturing capabilities for 2019-nCoV. The organization must be willing to transfer their vaccine technology to a global network of large-scale manufacturing.

Eligibility (if available)

Non-profit research organisations, for-profit companies, international organisations and foundations, joint R&D ventures, government research organisations, and academic institutions. Hold a vaccine technology that has already been proven. Propose only one 2019-nCoV vaccine candidate per application. Have the capacity to start vaccine manufacturing in at short notice. Be an organization that must be willing to transfer their vaccine technology to a global network
of large-scale manufacturers and ideally has its own large-scale manufacturing capabilities

Foreign participation? (where known)
Yes
Country
Date of announcement
Date application deadline